Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
01 nov. 2023 03h00 HE
|
Cellectis Inc.
Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate productsCellectis to receive up to $245M in cash...
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
31 oct. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
24 oct. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
24 oct. 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30...
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
12 oct. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis et l'Institut Imagine publient une étude de preuve de concept d'un candidat produit de chirurgie génique pour traiter le syndrome de la phosphoinositide 3-Kinase activée de type 1 (APDS1)
12 oct. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, 12 oct. 2023 (GLOBE NEWSWIRE) -- Cellectis (la " Société ") (Euronext Growth : ALCLS - NASDAQ : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière...
Date and Time Announced for First Wave BioPharma CEO James Sapirstein’s Presentation at the 2023 BIO Investor Forum
10 oct. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Societal CDMO Reports Inducement Grants for New Staff
05 oct. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Monthly information on share capital and company voting rights
03 oct. 2023 16h30 HE
|
Cellectis Inc.
PARIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference
03 oct. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...